Extraction of Pharmacokinetic Evidence of Drug-drug Interactions from the Literature

Artemy Kolchinsky^{1,2}, Anália Lourenço³, Heng-Yi Wu,⁴, Lang Li,⁴, Luis M. Rocha,^{1,2,*}

1 School of Informatics & Computing, Indiana University, Bloomington, IN, USA

2 Instituto Gulbenkian de Ciência, Portugal

3 IBB/CEB, University of Minho, Campus Gualtar, Braga, Portugal

4 Center for Computational Biology and Bioinformatics and Department of Medical &

Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA

∗ E-mail: rocha@indiana.edu

Abstract

Drug-drug interactions (DDIs) are major causes of morbidity and mortality and a subject of intense scientific interest. Biomedical literature mining can aid DDI research by extracting evidence for large numbers of potential interactions from published literature and clinical databases. While evidence for DDI ranges in scale from intracellular biochemistry to human populations, literature mining methods have not been used to extract specific types of experimental evidence which are reported differently for distinct experimental goals. We focus on *pharmacokinetic evidence* for DDIs, essential for identifying causal mechanics of putative interactions buried in the literature as well as input for further pharmacological and pharmaco-epidemiology investigation. We used a manually curated corpus of PubMed abstracts and annotated sentences to evaluate the efficacy of literature mining in classifying PubMed abstracts containing pharmacokinetic evidence for DDIs, as well as extracting sentences containing such evidence. We implemented a text mining pipeline using several linear classifiers and a variety of feature transformation methods. The most important textual features in the abstract and sentence classification tasks were analyzed. We also investigated the performance benefits of using features derived from PubMed metadata fields, from various publicly-available named entity recognizers and from pharmacokinetic dictionaries. Several classifiers performed very well in distinguishing relevant and irrelevant abstracts (reaching $F_1 \approx 0.93$, $MCC \approx 0.74$, $iAUC \approx 0.99$) and sentences $(F_1 \approx 0.76$, $MCC \approx 0.65$, $iAUC \approx 0.83$). We found that word-bigram textual features were important for achieving optimal classifier performance, that features derived from Medical Subject Headings (MeSH) terms significantly improved abstract classification, and that some drug-related entity named recognition tools and dictionaries led to slight but significant improvements, especially in classification of evidence sentences. Based on our thorough analysis of classifiers and feature transformation methods and the high classification performance observed, we demonstrate that literature mining can aid DDI discovery by supporting automatic extraction of specific types of experimental evidence.

Author Summary

Modern medicine is characterized by high prevalence and diversity of pharmaceutical treatments. Pharmaceuticals are often used in combination and can produce drug-drug interactions, including adverse side effects. There is great medical interest in identifying and preventing dangerous interactions, but the sheer number of possible drug combinations makes systematic clinical testing impractical. For this reason, one promising approach is to use automated methods to extract evidence of possible interactions from large electronic databases and the scientific literature; this evidence can subsequently serve as input for further pharmacological and pharmaco-epidemiology investigation. We show that we can reliably identify PubMed abstracts containing pharmacokinetic evidence of drug-drug interactions, as well as specific sentences that mention such evidence within relevant abstracts. The methodology is computationally feasible and achieves high accuracy on identifying both abstracts and sentences. We demonstrate that

literature mining can benefit translational pipelines for drug-drug interaction discovery that draw on specific kinds of evidence for interactions.

Introduction

Drug-drug interaction (DDI) is one of the major causes of adverse drug reaction (ADR) and a threat to public health. Based on statistics released in recent studies and publications by the National Health Statistics Report [\[1,](#page-18-0) [2\]](#page-18-1), as well as pharmaco-epidemiology studies on DDI [\[3\]](#page-19-0), each year an estimated 195,000 hospitalizations and 74,000 emergency room visits in the United States alone are the result of DDIs [\[4\]](#page-19-1). DDIs have been implicated in nearly 3% of all hospital admissions [\[5\]](#page-19-2) and 4.8% of admissions among the elderly [\[3\]](#page-19-0). DDIs are also a common consequence of medical error, representing 3% to 5% of all inpatient medication errors [\[6\]](#page-19-3). With increasing rates of polypharmacy, which refers to the use of multiple medications or more medications than are clinically indicated [\[7\]](#page-19-4), the incidence of DDI will likely increase in the coming years.

DDI research aims to link molecular mechanisms underlying DDIs to their clinical consequences, through three types of studies: in vitro, in vivo, and clinical $[8-10]$ $[8-10]$. In vitro pharmacology experiments use intact cells (e.g. hepatocytes), microsomal protein fractions, or recombinant systems to investigate molecular interaction mechanisms within the cell (i.e. metabolic, transportation- or target-based); In vivo studies evaluate whether such interactions impact drug exposure in humans; Clinical studies use a population based approach and large electronic medical record databases to investigate the contribution of a DDI to drug efficacy and ADRs.

Automated methods from biomedical literature mining (BLM) are a promising approach to extract evidence for a large number of potential DDIs whose pharmacological mechanisms and clinical significance can subsequently be studied with in vitro pharmacology as well as in vivo and clinical studies. BLM holds the promise of tapping into the biomedical collective knowledge [\[11\]](#page-19-7) and is becoming an important biomedical informatics methodology for large-scale information extraction from repositories of textual documents, as well as for integrating information scattered across various domain-specific databases and ontologies [\[12](#page-19-8)[–14\]](#page-19-9). It has been used for knowledge discovery in many biomedical problems, such as extraction of protein-protein interactions [\[15,](#page-19-10) [16\]](#page-19-11), protein structure prediction [\[17\]](#page-19-12), identification of genomic locations associated with cancer [\[18\]](#page-19-13), drug targets [\[19\]](#page-19-14), among others. In this context, BLM can be used to extract evidence of novel DDI signals from either the published literature or large clinical databases [\[20\]](#page-19-15).

BLM has previously been used for DDI information extraction [\[21–](#page-20-0)[27\]](#page-20-1), but much remains to be done in reliably extracting experimental evidence of DDI from text automatically. It is important to note that the experimental evidence of DDI is reported differently for the distinct types of studies described above. For instance, while in vivo pharmacokinetics experiments report parameters such as the 'area under the concentration-time curve', clinical studies may report population-level statistics of adverse drug reactions. To address this situation, we use BLM to perform the reliable extraction of pharmacokinetic evidence of DDI from in vitro and in vivo experiments. This important type of experimental evidence involves the measurement of pharmacokinetics parameters, such as the inhibition constant (Ki), the 50% inhibitory concentration (IC50), and the area under the plasma concentration-time curve (AUCR) which are not annotated in existing DDI corpora [\[28\]](#page-20-2) and thus not used to characterize DDI evidence in text mining approaches based on such corpora [\[27\]](#page-20-1). Pharmacokinetic evidence is particularly important in identifying or dismissing causal mechanisms behind DDIs and in providing support to putative DDIs extracted by mining patient records, where reporting biases and confounds often give rise to non-causal correlations [\[29\]](#page-20-3). Notice that pharmacokinetics experiments can result in positive or negative evidence, where the former indicates that the studied drugs interact while the latter indicates that the drugs do not interact. Both provide important information about possible DDI and our goal is to extract both types of evidence (see Materials and Methods section).

We have previously shown that BLM can be used for automatic extraction of numerical pharmacokinetics (PK) parameters from the literature [\[30\]](#page-20-4). However, that work was not oriented specifically toward the extraction of evidence of DDI. Recently, we have showed in preliminary work that it is possible to automatically classify PubMed abstracts which contain pharmacokinetic evidence of DDI, achieving very good performance [\[31\]](#page-20-5) (details below). However, identifying relevant abstracts is only a first step in a pipeline for extracting evidence of DDI from a pharmacokinetics perspective. Therefore, in this work we both identify abstracts describing the presence or absence of DDIs backed by pharmacokinetic evidence, and extract the sentences that contain such specific evidence. In addition to evidence-sentence extraction, we provide a new assessment of abstract classification based on an updated version of the corpus we recently published separately [\[26\]](#page-20-6), leading to substantial improvement of the classification performance reported in our preliminary study on abstract classification [\[31\]](#page-20-5). The updated corpus is described below and is publicly available. We also provide a new comparison of classifiers, a new evaluation methodology based on Principal Component Analysis (PCA) [\[32\]](#page-20-7) and significance tests, and a detailed study of the benefits of including features from PubMed metadata, named entity recognition and dictionary tools.

Our approach is different from related BLM approaches to DDI information extraction [\[21–](#page-20-0)[27\]](#page-20-1), particularly those related to the DDI Extraction challenges [\[27,](#page-20-1) [33–](#page-20-8)[35\]](#page-20-9), because the ultimate goal is not to identify the interacting drugs themselves but rather abstracts and sentences containing a specific type of evidence of drug interaction. Existing DDI-extraction approaches do not attempt to extract textual evidence for drug interactions. For instance, the DDI Extraction challenge '11 [\[33\]](#page-20-8) used a corpus of several hundred documents from DrugBank [\[36\]](#page-20-10) annotated with interacting drug pairs, without regard for experimental evidence. Similar recent work [\[22,](#page-20-11)[37\]](#page-20-12) has focused on large-scale extraction of drug-gene and drug-drug relationships from DrugBank without focusing on identifying or extracting experimental evidence. The more recent DDI Extraction challenge '13 [\[34\]](#page-20-13), provided a corpus annotated with pharmacokinetics and pharmacodynamics interactions [\[28\]](#page-20-2), but the goal of the text mining task was the extraction of interacting drug pairs and their classification, not the extraction of the experimental evidence of interaction itself. The same is true of a DDI network corpus recently produced from DrugBank data [\[38\]](#page-20-14), whose goal is to classify interacting versus non-interacting drug pairs using various types of evidence. Such a DDI network also does not serve the purpose of training classifiers to extract specific experimental evidence. The abstract and sentence corpora we developed and use (see below), were developed to annotate pharmacokinetics evidence of DDI, and include parameters not yet annotated in the corpora available in the literature. Moreover, since various types of evidence exist, it is important to demonstrate the ability to extract them independently. In the present work we focus on pharmacokinetic evidence, and in subsequent work we will approach other types of DDI evidence (e.g. clinical evidence). The DDI challenges [\[27,](#page-20-1) [28,](#page-20-2) [35\]](#page-20-9) and recent Pacific Symposium on Biocomputing sessions [\[39,](#page-21-0) [40\]](#page-21-1) provide a good overview of the literature on text mining methods in DDI research.

Using our own corpus means that our results are not directly comparable to other BLM approaches to DDI. Therefore, we pursued a thorough evaluation of different types of classifiers, feature selection, and normalization techniques. For both abstract and sentence classification we consider several linear classifiers: logistic regression, support vector machines (SVM), binomial Naive Bayes, linear discriminant analysis, and a modification of the Variable Trigonometric Threshold (VTT) classifier, previously developed by Rocha's lab and found to perform well on protein-protein interaction text mining tasks [\[11,](#page-19-7)[41,](#page-21-2)[42\]](#page-21-3). In addition, we compare different feature transform methods, including normalization techniques such as 'Term Frequency, Inverse Document Frequency' (TFIDF) and dimensionality reduction based on Principle Component Analysis (PCA). We also compare performance when including features generated by several Named Entity Recognition (NER) tools. Classifiers fall into two main classes, the behavior of which we describe in the results and discussion sections, based on whether or not they take into account feature covariance.

With the set of experiments we report here, our goal is to measure the quality of automated methods in identifying pharmacokinetic evidence of DDIs reported in the literature, and to demonstrate that literature mining methods perform well enough to be safely integrated into in DDI workflows to automatically extract experimental interaction evidence. A collaboration between Rocha's lab, working on BLM, and Li's lab, working on pharmacokinetics, was developed in order to pursue this goal. We show that many classifier configurations achieve high performance on this corpus, demonstrating the robustness and efficacy of BLM on extracting pharmacokinetic evidence of DDI.

Materials and Methods

Figure 1. Literature mining pipeline: The basic steps of the literature mining pipeline include selection of corpus documents, hand-labeling of ground truth assignments, extraction and normalization of textual features, and loading into unigram/bigram occurrences matrices. Cross-validation folds are used to estimate generalization performance of feature transformation and classifier configuration, with nested (inner) cross-validation folds are used to set classifier hyperparameters.

The following sections describe the methods of the literature mining pipeline. Its basic steps are visually diagrammed in figure [1.](#page-3-0) They include the selection of corpus documents, hand-labeling of ground truth assignments, extraction and normalization of textual features, and loading into unigram/bigram occurrences matrices. Cross-validation folds are used to estimate generalization performance of feature transformation and classifier configuration, with nested (inner) cross-validation folds used to set classifier hyperparameters. Software tools used were custom Python scripts, unless otherwise noted.

Abstract Corpus

For the training corpus, Li's lab selected 1203 pharmacokinetics-related PubMed abstracts. Documents were obtained by first searching PubMed using the terms from a previously developed ontology for PK pharmacokinetic parameters [\[30\]](#page-20-4). Therefore, all retrieved articles describe and contain some form of pharmacokinetic evidence. These articles are included in the publicly-available, manually-annotated abstractand sentence-level corpus we recently produced [\[26\]](#page-20-6). Abstracts were subsequently labeled relevant or irrelevant according to the following criteria: abstracts that explicitly mentioned experimental evidence for the presence or absence of drug-drug interactions were labeled as *DDI-relevant* (909 abstracts), while the rest were labeled as DDI-irrelevant (294 abstracts). DDI-relevance was established if articles contained either positive or negative evidence of interaction between two drugs, regardless whether the relevant enzyme was presented or not; experimental evidence must be based on unequivocal pharmacokinetics parameter data.

Notice that the concept of DDI-relevance we pursued here updates the previous criteria we used in a preliminary study [\[31\]](#page-20-5). Interactions between a drug and food, fruit, smoking, alcohol, and natural products are now also classified as drug interactions, because their pharmacokinetics studies are designed similarly. For the same reason, we now also consider as relevant, studies dealing with interactions between drug metabolites, instead of parent compounds, as well as inhibition of induction of a drug on a drug metabolism enzyme or drug transporter. We kept in vitro studies, but removed any animal in vivo studies. Classification was done by three graduate students with M.S. degrees and one postdoctoral annotator; any inter-annotator conflicts were checked by a Pharm D. and an M.D. scientist with extensive pharmacological training. The corpus is publicly available as "Pharmacokinetics DDI-Relevant Abstracts V0" in [\[43\]](#page-21-4).

We extracted textual features from the article title and abstract text, as well as several PubMed metadata fields: the author names, the journal title, the Medical Subject Heading (MeSH) terms, the 'registry number/EC number' (RN) field, and the 'secondary source' field (SI) (the latter two contain identification codes for relevant chemical and biological substances). For each PubMed entry, the content of the above fields was tokenized, processed by Porter stemming [\[44\]](#page-21-5), and converted into textual features (unigrams and, in certain runs, bigrams). Strings of numbers were converted into \dddot{H} , short textual features (with length of less than 2 characters) and infrequent features (that occurred in less than 2 documents) were omitted. Author names, journal titles, substance names, and MeSH terms were treated as single textual tokens.

The corpus was represented as binary term-document occurrence matrices. We evaluated performance under two different conditions: in the first – referred to as 'unigram runs' – only word unigram features were used; in the second – referred to as 'bigram runs' – word bigram features were used in addition to the unigram features. Thus, bigram runs included a much larger number of parameters – i.e. the bigram feature coefficients – that needed to be estimated from training data, which can potentially increase generalization error arising from increased model complexity [\[45\]](#page-21-6). Running the classifiers exclusively with unigram features and with both unigram and bigram features allows us to test if the class information provided by bigrams outweights their cost in complexity.

Sentence Corpus

The evidence sentence task consisted of identifying those sentences within a PubMed abstract that reported experimental evidence for the presence or absence of a specific DDI. For this purpose, Li's group developed a training corpus of 4600 sentences extracted from 428 PubMed abstracts. All abstracts contained pharmacokinetic positive or negative evidence of DDIs, and included at least one evidence sentence. Sentences were manually labeled as DDI-relevant (1396 sentences) if they explicitly mentioned pharmacokinetic evidence for the presence or absence of drug-drug interactions, and as DDI-irrelevant (3204 sentences) otherwise. The same pre-processing and annotation procedures were followed for the sentence corpus as for the abstract corpus (see section "Abstract Corpus"). More information about this corpus is provided in [\[26\]](#page-20-6); it is also publicly available as "Deep Annotated PK Corpus V1" in [\[43\]](#page-21-4).

Classifiers

Six different linear classifiers were implemented:

1. VTT: a simplified, angle-domain version of the Variable Trigonometric Threshold Classifier, pre-viously developed in Rocha's lab [\[11,](#page-19-7)[41,](#page-21-2)[42\]](#page-21-3). Given a document vector $\mathbf{x} = \langle x_1, \ldots, x_K \rangle$, with its features (i.e. dimensions) indexed by i, the separating hyperplane is defined as $\sum_i \theta_i x_i - \lambda = 0$. Here, λ is a threshold (bias) and θ_i is the 'angle' of feature i in binary class space: $\theta_i = \arctan \frac{p_i}{n_i} - \frac{\pi}{4}$, where $p_i(n_i)$ is the probability of occurrence of feature i in relevant-class (irrelevant-class) documents. The threshold parameter λ is chosen as the midpoint between the mean values of p_i and n_i for each class. The full version of VTT, previously used in protein-protein interaction tasks, includes additional parameters to account for named entity occurrences and is used in section "Impact of NER and PubMed metadata on abstract classification" below to test various NER tools. VTT performs best on sparse, positive datasets; for this reason, we do not evaluate it on dense dimensionality-reduced datasets below. Notice that in previous work, we used a different version of VTT with a cross-validated threshold parameter; its performance on the tasks was very similar, and is reported in the Supporting Information under the 'VTTcv' classifier (section 1 and 2 in Text S1).

2. SVM: a linear Support Vector Machine (using the sklearn [\[46\]](#page-21-7) library's interface to the LIBLINEAR package [\[47\]](#page-21-8)) with a cross-validated regularization parameter.

3. Logistic regression classifier (also provided by sklearn's interface to LIBLINEAR) with a crossvalidated regularization parameter.

4. Naive Bayes classifier with smoothing provided by a Beta-distributed prior with a cross-validated concentration parameter.

5. LDA: a regularized Linear Discriminant Analysis classifier, following [\[48\]](#page-21-9). Singular value decomposition (SVD), a dimensionality-reduction technique, is first used to reduce any rank-deficiency, after which the covariance matrix is shrunk toward a diagonal, equal-variance structured estimate. The shrinkage parameter is determined by cross-validation.

6. dLDA: a 'diagonal' LDA, where only the diagonal entries of the covariance matrix are estimated and the off-diagonal entries are null. A cross-validated parameter determines shrinkage toward a diagonal, equal-variance estimate. This classifier can offer a more robust estimate of feature variances; it is equivalent to a Naive Bayes classifier assuming multivariate Gaussian features [\[49\]](#page-21-10).

Generally, linear classifiers fall into one of two types. The first, sometimes called 'naive' in the literature, learns feature weights without considering features covariances. In our case, this includes VTT, dLDA, and Naive Bayes classifiers. These classifiers often perform well because, while feature covariances can include useful information about class boundaries, covariances are difficult to estimate accurately with small amounts of training data and variance in their estimates may in fact degrade classification performance. The other type, which we refer to as 'non-naive' and which is represented by SVM, LDA, and Logistic Regression classifiers, does take into account feature covariances (commonly using regularization techniques to smooth covariance estimates) and can achieve superior performance given enough training data.

Feature Transforms

For both unigram and bigram runs, the classifiers were applied to the following data matrices:

1. No transform: raw binary occurrence matrices (see section "Abstract Corpus").

2. IDF: occurrences of feature i were transformed to its Inverse Document Frequency (IDF) value: $\text{if}(i) = \log \frac{N}{c_i+1}$, where c_i is the total number of occurrences of feature i among all documents. This reduced the influence of common words on classification.

3. TFIDF: the Term Frequency, Inverse Document Frequency transform; same as above, but subsequently divided by the total number of features that occur in the document. This attempts to reduce the impact of document size differences.

4. Normalization: the non-transformed, IDF, and TFIDF document matrices underwent a lengthnormalization transform, where each document vector was inversely scaled by its L2 norm. Such L2 normalization has been argued to be especially important for good SVM performance [\[50\]](#page-21-11).

5. PCA: The above matrices were run through a Principal Component Analysis (PCA) dimensionality reduction step. Projections onto the first 100, 200, 400, 600, 800, and 1000 components were tested.

Feature transformations can improve classification performance by altering the distributions of document vectors to make class-separating surfaces more linear and to decrease the weight of nondiscriminating features. PCA, on the other hand, reduces the number of parameters that need to be estimated from training data. If class membership information is contained in the subspace spanned by the largest principal components, then this kind of dimensionality reduction can improve generalization performance by reducing noise and model complexity. By testing feature transforms and PCA-based dimensionality reduction we investigate the effect such techniques on classification performance in our DDI evidence tasks.

Performance evaluation

The document and sentence corpora described above were used both for training classifiers and for estimating generalization performance on out-of-sample documents and sentences, respectively. In order to get an estimate of out-of-sample performance, we used the following cross-validation procedure:

1. Each corpus was randomly partitioned into 4 document folds (75%-25% splits). This was repeated 4 times, yielding 16 outer folds. All configurations were evaluated under the same partitions.

2. For each fold, classifiers were trained on the 75%- and tested on the 25%-block of the corpus.

3. The 16 sets of testing results were averaged to produce an estimate of generalization performance. Except for VTT, the classifiers listed in section "Classifiers" use cross-validated regularization parameters. These parameters are not chosen using cross-validation on the above outer folds, since this would lead to a biased estimate of out-of-sample performance. Instead, training and testing data are separated by performing nested cross-validation within each of the 75% blocks of the above outer folds:

1. The 75%-block is itself partitioned into 4 folds (75%-25% splits of the outer 75% block). This is repeated 4 times, producing a total of 16 inner folds

2. Over a range of values of the cross-validate parameter, a classifier is trained on the 75%- and tested on the 25%-block of each of the 16 inner folds. Its mean performance using the Matthews Correlation Coefficient [\[51\]](#page-21-12) (MCC), is recorded; this measure is particularly well-suited for the unbalanced scenarios of our corpora [\[52\]](#page-21-13).

3. The parameter value giving the best mean performance is chosen as the cross-validated parameter value for the outer fold, and used to train on the 75%- and test on the 25%-block of the outer fold.

It should be re-iterated that because training and testing documents are always separated, for each cross-validation fold the above procedure is equivalent to calculating performance on an independent testing corpus.

We evaluated the performance of the classifiers using three different measures: the balanced F1 score (the harmonic mean of precision and recall), the iAUC or 'area under the interpolated precision/recall curve' [\[53\]](#page-21-14), and the MCC. In addition, we computed and reported the rank product of these three measures (RP3) as a single inclusive metric of classification performance. The RP3 measure provides a well-rounded assessment of classifier performance, as it combines the ranking of the different individual measures [\[11,](#page-19-7) [41\]](#page-21-2). However, for displaying results, we focus most prominently on the iAUC measure (in cases where only plots of iAUC performance are provided, F1 and MCC plots are found in the Supporting Information). Though iAUC looks at the ranking of test-set documents (from most relevant to most irrelevant, according to classifier confidence scores) and ignores actual class assignments, it offers three major advantages. First, it provides a richer measure of overall classifier performance because it evaluates the entire ranking of documents and not just class assignments. Second, iAUC is less sensitive to variation driven by random-sampling differences in the training corpus, which may lead to fluctuations in the class

assignments of low confidence documents and, correspondingly, high variability in measures such as F1 and MCC. Finally, it is more relevant in a frequently-encountered situation where a BLM pipeline includes a human practitioner interested in either retrieving the most relevant documents, or in re-validating the most-likely-to-be-misclassified documents (for a configuration with good iAUC performance, the ranks of these will cluster together).

Both the abstract and sentence classification tasks are characterized by imbalanced datasets, with more relevant-class abstracts and more irrelevant-class sentences respectively. Because we are primarily concerned with relative changes in ranking performance (as measured by iAUC) between different machine learning configurations on the same dataset, and due to considerations of simplicity, we do not perform resampling or re-weighting of training items. In addition, we report MCC values, a measure of classification performance that is known to be stable in the face of unbalanced classes [\[52\]](#page-21-13).

The performance of a classifier and data transform configuration varies both due to random sampling of folds, and due to the inherent performance bias of the configuration over the entire distribution of folds. Since we are only interested in the latter, statistical testing was done on performance differences observed between pairs of configurations. We used a non-parametric paired-sample permutation test: the assignments of the 16 outer folds were permuted between the two configurations in the pair; the set of mean-fold performance differences across all 2^{16} possible permutations generates the null hypothesis distribution of performance differences under the assumption that the two configurations have equal performance; a p-value of the actually-observed performance difference can then be computed from this null hypothesis distribution.

Results

Abstract classification performance

Figure 2. Classification performance on abstracts: Performance shown using non-transformed features for both unigram and bigram runs. Left: F1 measure. Middle: MCC measure. Right: iAUC measure. The best classifier configuration, and configurations not significantly different $(p>0.05$, one-sided test) from it, marked with asterisk '*'.

Figure [2](#page-7-0) depicts classifier performance on the abstract classification task for the unigram and bigram runs with no feature transforms applied. The best classifier configuration, as well as those configurations not significantly different from the best $(p>0.05,$ one-sided test), are marked with an asterisk. In addition, the numeric results, ranks, and the rank-product (RP3) measure are reported in table [1.](#page-8-0) The results summarized in this table and figure denote excellent performance on the abstract classification task, reaching $F_1 \approx 0.93$, $iAUC \approx 0.98$, $MCC \approx 0.73$. This performance constitutes a substantial and significant improvement over our previous preliminary results reported in [\[31\]](#page-20-5), where we had reached $F_1 \approx 0.8$, $\text{AUC} \approx 0.88$, $\text{MCC} \approx 0.6$ (notice that these performance values would be well below

Classifier	Type	F1	мсс	iAUC	RP3
LDA	Bigram	.931(1)	.728 (1)	.984(1)	
Log Reg	Bigram	(2) .929	.698(3)	.984(1)	6
SVM	Bigram	(3) .928	.693(4)	.983(3)	36
LDA	Unigram	(6) .926	.719 (2)	.983(3)	36
Log Reg	Unigram	(4) .927	.689(5)	.980(6)	120
SVM	Unigram	(4) .927	.689(5)	.980(6)	120
Naive Bayes	Bigram	.920(7)	.661(10)	.981(5)	350
Naive Bayes	Unigram	(8) .919	.672(7)	.978(9)	504
VTT	Bigram	(8) .919	.656(12)	.980(6)	576
VTT	Unigram	(10) .918	.662(9)	(10) .977	900
dLDA	Bigram	.909(11)	.670(8)	.975(11)	968
dLDA	Unigram	.908(12)	.658(11)	.974 (12)	1584

Table 1. Classification performance on abstracts: Performance of different abstract classifiers and feature types without feature transforms; ordered according to rank product (last column) of ranks of F1, MCC, and iAUC performance measures. The ranks of each measure are reported in parenthesis in respective column.

the lowest reported levels in Figure [2\)](#page-7-0). This demonstrates that the more carefully curated corpus we use here, which now considers interactions between drugs and food, fruit, smoking, alcohol, and natural products to be relevant (details in "Materials and Methods Section"), improves the classification of abstracts with pharmacokinetic evidence of DDI. The levels of performance achieved are excellent, also when compared to similar abstract classification tasks in other biomedical domains. For instance, in the BioCreative Challenge III, considered one of the premier forums for assessment of text mining methods, the best classifiers of abstracts with Protein-Protein Interaction yielded performances with $F_1 \approx 0.61, iAUC \approx 0.68, MCC \approx 0.55$ [\[16\]](#page-19-11). Naturally, our results are not directly comparable to results obtained on different corpora and on a different problem, but these numbers highlight what is typically considered a good result in biomedical article classification.

Comparing the various alternatives in our experiments, we can see that bigram features yielded superior performance according to all measures and all configurations. The best classifier according to all measures was LDA using bigrams. The performance of this classifier was significantly better than all others for the MCC, but not significantly better to Logistic Regression according to the iAUC, and not significantly better that Logistic Regression and SVM according to the F1 score. According to RP3, these three classifiers using bigrams yield the best performance. Not surprisingly, Naive Bayes, VTT, and dLDA, which are classifiers that make a 'naive' independence assumption about features, in that they do not consider feature covariances when learning hyperplane coefficients (see "Materials and Methods" section), performed below the top three. However, the performance levels they achieved are still quite high, which indicates that such simple classifiers are also capable of classifying documents with pharmacokinetic DDI evidence. The in-house VTT classifier, which is the only classifier tested here without cross-validated parameters, was originally developed to work in tandem with NER features [\[11,](#page-19-7) [41,](#page-21-2) [42\]](#page-21-3), a situation where it behaves better as shown below.

Feature Transforms and Dimensionality Reduction

The different feature transforms and PCA-based dimensionality reductions (section "Materials and Methods") did not improve on the performance of the best non-transformed classifier, but did significantly improve performance for a few given classifiers. Details are provided in Supporting Information (section 1.1 in Text S1). In summary, according to most measures, only dLDA and SVM improved performance significantly with an IDF-like (either IDF or TFIDF) transform plus L2 normalization, plus dimensionality reduction (top n principal components). For instance, the best iAUC for SVM (0.984) occurs

with a dimensionality reduction to the top 800 principal components and no feature transform; this is a significant improvement over the no-transform, no dimensionality reduction SVM classifier reported in Table [1](#page-8-0) and Figure [2,](#page-7-0) but not a significant improvement over the overall best classifiers there reported (LDA and Logistic regression). The dLDA classifier significantly improves its iAUC performance with almost all feature transform and dimensionality reduction combinations, but not above that of the top performing classifiers. Therefore, we conclude that feature transforms and dimensionality reduction does not significantly improve classification performance of abstracts with pharmacokinetic evidence of DDI.

Pharmacokinetics DDI Features in abstract classification

Table 2. Top 20 relevant and irrelevant abstract features: The stemmed textual features most discriminative of relevant and irrelevant classes on the abstract task, as chosen by two of the top-performing classifiers according to the RP3 measure: LDA on bigrams (left) and Logistic Regression on bigrams (right).

We analyzed classifier parameters in detail to identify which textual features play the largest role in the abstract classification task. A linear classifier separates classes using a hyperplane defined by a set of feature coefficients. The impact of a feature on classification is quantified by the sign and amplitude of its hyperplane coefficient. A feature with a large positive (negative) coefficient contributes strongly to a document's propensity to be classified as relevant (irrelevant). In table [2,](#page-9-0) we show the top 20 features most distinctive of the relevant and irrelevant classes in the abstract task (notice they are stemmed), as chosen by the LDA classifier (left) and Logistic Regression classifier (right) using bigram features (the two top-performing classifiers in this task according to the RP3 measure; see Table [1\)](#page-8-0).

Some of the most relevant features come from MeSH term metadata (such as the MeSH term Drug interactions) and terms that explicitly indicate interactions ('interact', 'inhibit', 'interact between', 'decreas', 'increas'). Other relevant terms deal with administration protocols and study design ('oral', 'day', 'receiv', 'mg', 'treatment', 'alon', 'combin'). Some of the irrelevant features concern genetics terminology ('allel', 'genotyp', 'polymorph', and 'MeSH:Phenotype'), indicating that the irrelevant class was enriched with genetics or pharmacogenetics evidence not dealing with drug interactions. Several generic biomedical

terms (such as 'patient', 'healthi subject', 'higher') terms are also highly irrelevant. In addition, highly irrelevant features also contain some non-DDI-specific pharmacokinetic terms (for example, 'area', 'rate', 'clearance of'), which is not surprising given that both relevant and irrelevant articles were generally drawn from pharmacokinetic-related literature. One surprising result is the observation that while the term 'MeSH:Male' is one of the top relevant features, the term 'MeSH:Female' is one of the top irrelevant features; we have no explanation for the cause of this gender imbalance, since the corpus was built from automatic searches to PubMed without any gender specific pharmacokinetic query terms.

Further analysis of highly relevant and irrelevant features across all classifiers and feature transforms was performed and reported in the Supporting Information (section 1.2 in Text S1). We quantified and plotted the contribution of standardized coefficients [\[54\]](#page-21-15) of different features, and looked at the most positively and negatively loaded features for different classifier and transform configurations. The textual features obtained from all classifiers pick additional terms that fall in the same categories described above, though additional features derived from PubMed metadata (MeSH, chemical substances) also appear both among the most relevant and irrelevant sets. In addition to the two highly-relevant MeSH terms mentioned above, other relevant MeSH terms include: MeSH:Cimetidine/pharmacology, MeSH:Cross-Over Studies, MeSH:Enzyme Inhibitors/PK, MeSH:Kinetics, and MeSH:Proton Pump Inhibitors. Additionally, a prominent researcher author ('PJ Neuvonen') in the pharmacokinetics DDI field appears, as well as three substances from the RN field (see also section "Impact of NER and PubMed metadata on abstract classification" below): 'Cimetidine', 'Enzyme Inhibitors', and 'Proton Pump Inhibitors'. For the irrelevant set, additional MeSH and Substance terms also appear: 'MeSH:Anti-Ulcer Agents/adm&dos', 'MeSH:Injections, Intravenous', 'MeSH:Phenotype', 'MeSH:Protein Binding', 'MeSH:Reference Values', 'Substance:Anti-ulcer agents', 'Substance:Hydrocarb. Hydroxylas'. The Supporting Information contains details of the analysis and lists of features. It also shows the results of a Principal Component Analysis of feature weight coefficients chosen by different classifiers.

Impact of NER and PubMed metadata on abstract classification

Figure 3. Performance impact of abstract NER and metadata features: Left: Relative changes in iAUC scores on non-transformed abstract bigram runs in combination with different $NER/Dictionary$ features. Significant changes ($p<0.05$, two-tailed test) in performance over the respective classifiers without NER features are indicated with asterisk. Right: Relative changes in iAUC when features from a given PubMed metadata field are included versus omitted (while including features from the other 4 metadata fields). Significant changes ($p<0.05$, two-tailed test) in performance are indicated with asterisk.

We have previously used *Named Entity Recognition* (NER) and domain-specific *dictionary* tools to extract features that improve classification performance on similar protein-protein interaction text mining tasks [\[11,](#page-19-7)[41,](#page-21-2)[42\]](#page-21-3); NER and dictionary features were used to supplement textual features such as the word unigram and bigram occurrences, as used above. To test if similar techniques are useful in the DDI domain, we counted mentions of named biochemical species (e.g. proteins, compounds and drugs) in each document and then included such counts as document features, in addition to the bigram and unigram textual features. Counts were extracted using biomedical-specific NER extraction tools and dictionaries, with dictionary matches identified by internally-developed software. A preliminary study of the impact of NER/Dictionary features was reported in [\[31\]](#page-20-5) using a previous less-refined DDI corpus. Here, in addition to using the more fine-tuned corpus (see "Methods and Data" section), we study the impact of PubMed metadata features on classification performance. We also provide a new comprehensive analysis of the performance impact of including features from the various publicly-available NER and metadata resources utilized in this study:

- OSCAR4 [\[55\]](#page-21-16): NER tool for chemical species, reaction names, enzymes, chemical prefixes and adjectives.
- ABNER [\[56\]](#page-21-17): NER tool for genes, proteins, cell lines and cell types.
- BICEPP [\[57\]](#page-21-18): NER tool for clinical characteristics associated with drugs.
- *DrugBank* database [\[58\]](#page-21-19): a dictionary list of drug names
- Dictionaries provided by Li's lab: $i-CYPS$ for cytochrome P450 [CYP] protein names, a group of enzymes centrally involved in drug metabolism; i - $RkParams$ – for pharmacokinetic parameters; i -Transporters – for proteins involved in transport; i -Drugs – for Food and Drug Administration's drug names. The dictionaries are available for download from [http://rweb.compbio.iupui.edu/](http://rweb.compbio.iupui.edu/corpus/downloads.html) [corpus/downloads.html](http://rweb.compbio.iupui.edu/corpus/downloads.html).

For each of these NER tools and dictionaries, we counted the number of occurrences of any of its entities/entries in a given abstract. These counts were treated as any other feature for SVM, Logistic Regression, diagonal LDA, and LDA classifiers. Naive Bayes was omitted since NER count features are non-binary. VTT incorporates NER features via a modified separating hyperplane equation:

$$
\sum_i \theta_i x_i - \sum_j \frac{\beta_j - c_j}{\beta_j} - \lambda = 0
$$

where x_i represents the occurrence of textual feature i, θ_i and λ are textual feature and bias parameters as described in section "Classifiers", c_j is the count of NER/Dictionary features produced by resource j, and β_i is a weighting term for resource j, chosen by cross-validation.

In figure [3](#page-10-0) (left), we plot the relative iAUC changes over the respective classifiers without NER/Dictionary count features (results for MCC and F1 in Supporting Information; section 1.3 in Text S1). Significant performance changes are indicated with an asterisk $(p<0.05,$ two-tailed test). A few NER/Dictionary features improved performance significantly for several classifiers – though including two dictionary features ($DrugBank$, and $i-CYPS$) actually decreased performance significantly for a few classifiers (such decreases in generalization performance indicate that $DrugBank$ and $i-CYPS$ counts are noisy features that contain little class information and instead contribute to over-fitting). Table [3](#page-12-0) lists the performance according to all measures for classifiers using the NER and dictionary features which yielded a significant performance increase for at least one of the three measures; also listed are the corresponding best classifiers using textual features (bigrams and unigrams). The BICEPP tool yielded the best improvement consistently for every classifier tested, followed by the i -Drugs dictionary. The OSCAR4 tool also improved significantly the performance of the VTT classifier (especially for the MCC measure as shown in Supporting Information). With the inclusion of NER and dictionary features, the overall top classifiers (LDA and Logistic Regression), improved significantly their performance now reaching

Classifier	NER	F1	мсс	iAUC	RP3
LDA	BICEPP	.933(2)	.737 (1)	.985(1)	$\overline{2}$
LDA	i-Drugs	(1) .934	.736 (2)	.985(1)	$\overline{2}$
Log Reg	BICEPP	.933 (2)	.714 (3)	.985 (1)	8
Log Reg	<i>i-Drugs</i>	.930 (6)	.700 (6)	(1) .985	36
LDA		.931 (5)	.728 (3)	.984 (5)	75
SVM	BICEPP	.932(4)	.710 (5)	.984(5)	100
Log Reg		(8) .929	.698 (7)	.984 (5)	280
SVM	<i>i-Drugs</i>	.930(6)	.687 (10)	.984(5)	300
SVM		.928(9)	.693 (8)	.983(9)	648
VTT	BICEPP	.922(11)	.692(9)	.980(12)	1188
VTT	OSCAR4	.923(10)	.683(11)	.979 (14)	1540
VTT	<i>i-Drugs</i>	.920(12)	.670(14)	.981(10)	1680
Naive Bayes		.920(12)	.661(16)	.981(10)	1920
dLDA	BICEPP	.911(15)	.680(12)	.976(15)	2700
VTT		.919(14)	.656 (17)	.980(12)	2856
dLDA	<i>i-Drugs</i>	.911(15)	.678 (13)	.975(16)	2700
dLDA		.909 (17)	.670 (14)	.975 (16)	3808

Table 3. Classification performance on abstracts using NER features: Performance of the best classifiers when specific NER and dictionary features are added; original (bigrams and unigrams) classifiers also listed with no NER features. (indicated by −) Performance ordered according to rank product (last column) of ranks of F1, MCC, and iAUC performance measures. The ranks of each measure are reported in parenthesis in respective column.

Word unigram and bigram features were extracted not only from article abstracts and titles, but also from five PubMed metadata fields: author names, journal titles, MeSH terms, and two fields referring to standardized substance names, the 'registry number/EC number' [RN] field and the 'secondary source' field [SI]. Interestingly, some PubMed metadata features were among those most distinguishing of relevant and irrelevant abstracts; for greater detail, see table [2](#page-9-0) and section "Pharmacokinetics DDI Features in abstract classification", as well Supporting Information (section 1.2 in Text S1). We tested the impact of PubMed metadata fields on abstract classification performance. In figure [3](#page-10-0) (right), we plot the relative iAUC changes when features from a given PubMed metadata field are included versus omitted (while including features from the other 4 metadata fields). Significant changes ($p<0.05$, two-tailed test) in performance are indicated with an asterisk; results for MCC and F1 can be found in Supporting Information. MeSH terms was the only metadata source whose omission decreased performance significantly. Notice, however, that the performance increase of including MeSH data is rather small. Therefore, the methodology does not require the availability of human-annotated metadata such as MeSH terms and can thus be deployed on recent articles that have not yet been annotated with MeSH terms—according to ELM statistics, on average it takes 90 days from publication for 75% of articles in PubMed to be indexed with MeSH terms. Some articles are never indexed.

Evidence sentence extraction performance

Figure [4](#page-13-0) shows the performance of the sentence classifiers using unigram and bigram features, without any feature transforms applied, according to F1, MCC, and iAUC measures. The best classifier configuration, as well as those configurations not significantly different from the best $(p>0.05,$ one-sided test), are marked with an asterisk. In addition, the numerical results, ranks, and the rank-product (RP3) measure are reported in table [4.](#page-13-1)

Figure 4. Sentence classification performance: Show for non-transformed features for both unigram and bigram runs. Left: F1 measure. Middle: MCC measure. Right: iAUC measure. The best classifier configuration, and configurations not significantly different $(p>0.05,$ one-sided test) from it, marked with asterisk '*'.

Classifier	Type	F1	MCC	iAUC	RP3
LDA	Bigram	.752(1)	.642(1)	.826(1)	1
LDA	Unigram	.750(2)	.636(2)	.819(4)	16
SVM	Bigram	.736 (3)	.633(3)	.824(2)	18
Log Reg	Bigram	.734 (7)	.630(4)	(3) .823	84
SVM	Unigram	.735(6)	.630(4)	.819(4)	96
VTT	Bigram	.736 (3)	.617(8)	.797 (7)	168
Naive Bayes	Unigram	.736(3)	.617(8)	.791(10)	240
Log Reg	Unigram	.734(7)	.629(6)	.818 (6)	252
Naive Bayes	Bigram	.734(7)	.619(7)	.796(8)	392
dLDA	Unigram	.732(11)	.613(10)	.790(11)	1210
dLDA	Bigram	.710(12)	.600(12)	.794(9)	1296
VTT	Unigram	.733 (10)	.606(11)	.789 (12)	1320

Table 4. Sentence classification performance: Performance of different sentence classifiers and feature types without feature transforms; ordered according to rank product (last column) of ranks of F1, MCC, and iAUC performance measures. The ranks of each measure are reported in parenthesis in respective column.

Including bigram features tended to improve sentence classification performance, as with abstracts. LDA performed the best, having the highest RP3 and being significantly the best classifier according to the F1 and MCC measures and one of the two significant best classifiers (along with SVM) on the iAUC measure. Generally, the classifiers that performed best on the sentence task were also those that took advantage of feature covariances: SVM, Logistic Regression, and LDA. The top classifier (LDA with bigrams) on the evidence sentences task reaches: $F_1 \approx 0.75$, $MCC \approx 0.64$, $iAUC \approx 0.83$.

We measured sentence classification performance in combination with different feature transforms and dimensionality reductions (see section 2.1 in Text S1). In general, the three classifiers that do best on non-transformed data – SVM, Logistic Regression, and LDA – show decreased performance with dimensionality reduction according to all measures, with more extreme dimensionality reduction leading to larger performance decreases. On the other hand, for dLDA (a 'naive' classifier that treats features as independent), PCA-based dimensionality reduction – which uses feature covariances to choose optimal projections – led to significant improvements in all measures, with more dimensions giving better performance. These findings indicate that the pattern of feature covariation carries important information about class membership in the sentence task, and that this pattern is distributed across a large number of dimensions. Generally, the LDA classifier achieved the best performance according to all three measures.

Its baseline performance according to the iAUC measure was further improved significantly by an IDFtransform, and by any transform containing an L2 normalization according to the F1 measure.

Table 5. Top 20 relevant and irrelevant sentence features: The features most discriminative of relevant and irrelevant classes on the sentence task, as chosen by the top-performing classifiers according to the RP3 measure: LDA on bigrams.

In table [5,](#page-14-0) we show the top 20 features most distinctive of the relevant and irrelevant classes in this task, as chosen by the LDA classifier on bigrams (the top performing classifier on the RP3 measure; features of other top classifiers are not shown because they were highly similar). Numerical features (indicated by $\sharp \sharp \sharp$) were highly indicative of the relevant sentence class, as were also expressions of quantitative changes ('decreas', 'increas') and interaction ('inhibit', 'catalyz', 'interact with'), as well as adverbs expressing significance of evidence ('significantli'). Also highly relevant were features referring to the area under the concentration-time curve ('auc'), which is often employed in pharmacokinetics to measure differences in drug clearance under different experimental conditions. Drug names, such as ('ketoconazol', 'itraconazol', 'quiindin'), are relevant in predicting DDI sentences. They are frequently used probe inhibitors for metabolism enzymes CYP3A4/5, CYP3A4/5 and CYP2D6 respectively, and are routinely used in the drug interaction studies.

Highly irrelevant features refer to more generic pharmacokinetic or biomedical concepts, such as 'investig', 'dose', 'enzym', 'studi', etc. Interestingly, some terms that are highly relevant in the abstract task are highly irrelevant in the sentence task (e.g., 'day'); notably, the unigram 'interact' is in the irrelevant class for sentences, whereas the bigram 'interact with' is in the relevant class. This may be because all sentences in this corpus come from abstracts containing pharmacokinetic DDI evidence and words referring to experimental design (see "Materials and Methods" section). Thus, general administration protocols and drug interaction terms are likely to occur in the abstract as a whole but not specifically in the evidence sentences, which focus on reporting pharmacokinetic outcomes of the drug interaction experiments. Similar patterns are observed in the more extensive analysis provided in Supporting Information (section 2.2 in Text S1), where we analyze relevant and irrelevant features across a wide range of classifier and feature transform configurations. We also show the results of a Principal Component Analysis of feature weight coefficients chosen by different classifiers.

Figure 5. Performance impact of sentence NER features: Relative changes in iAUC scores on sentence bigram runs (without transforms or dimensionality reductions) in combination with different NER features. Significant changes ($p<0.05$, two-tailed test) in performance over respective classifiers without NER features are indicated with asterisk.

Finally, we tested the impact of additional features on classification. There is no metadata available in the sentence corpus, but it is still possible to look at whether including NER features improved performance. Six NER features were tested: BICEPP, DrugBank, i-CYPS, i-Drugs, i-PkParams, i-Transporters (see section "Impact of NER and PubMed metadata on abstract classification" for details). As before, we counted mentions of named biochemical species specified by different NER tools in each sentence and then included such counts as sentence features, in addition to the bigram and unigram textual features. Figure [5](#page-15-0) shows relative iAUC changes when features from each of these NER tools were included. Significant improvements $(p<0.05,$ two-tailed test) above the corresponding classifier's performance without NER features are indicated by an asterisk; performance according to MCC and F1 measures is shown in Supporting Information (section 2.3 of Text S1). Notice that Naive Bayes was omitted since NER count features are non-binary.

A few NER/Dictionary features again improved performance significantly for several classifiers. The iAUC scores of nearly all classifiers were significantly improved by three NER tools: BICEPP, DrugBank, and our internally developed *i-Drugs* dictionary, but the BICEPP tool yielded the largest improvement for every classifier. Table [6](#page-16-0) lists the performance according to all measures for classifiers using the BICEPP features; also listed are the corresponding best classifiers using textual features (bigrams and unigrams). With the inclusion of these NER features, the overall top classifiers (LDA and SVM) showed significantly improved performance, reaching $F_1 \approx 0.76$, $MCC \approx 0.65$, $iAUC \approx 0.83$. In addition, with the inclusion of NER features, VTT performance improved significantly for all three measures, reaching a rank above most non-naive classifiers without NER features. This is an expected result since VTT was designed specifically to handle such NER features [\[11,](#page-19-7) [41,](#page-21-2) [42\]](#page-21-3). In contrast, dLDA (another "naive" classifier) did not benefit much from the inclusion of NER features. The three NER and dictionary tools that improved performance detect mentions of drug names, indicating that drug-name counts do help in classifying sentences as DDI-relevant or DDI-irrelevant.

It is also noteworthy that including the $i-PkParams$ feature, which counts occurrences of pharmacokinetic parameters in sentences, actually decreased iAUC performance significantly for the dLDA and LDA classifiers. Since the DDI evidence we want to extract is from pharmacokinetics experiments, this result is somewhat surprising and indicates that actual evidence of drug interaction is not necessarily conveyed in sentences that mention pharmacokinetics parameters themselves, which may appear elsewhere in the text—the entire sentence corpus is derived from abstracts which are relevant for pharmacokinetics experimental evidence of DDI (see "Materials and Methods" section).

Table 6. Sentence classification performance with NER features: Performance of different sentence classifiers with the count feature obtained via the BICEPP NER tool; original (bigrams and unigrams) classifiers also listed with no NER features (indicated by −). Classifiers are ordered according to rank product (last column) of ranks of F1, MCC, and iAUC performance measures. The ranks of each measure are reported in parenthesis in respective column.

Discussion

We have demonstrated that current BLM methods for text classification can reliably identify PubMed abstracts containing pharmacokinetic evidence of drug-drug interactions, as well as specific sentences that mention such evidence within relevant abstracts. Indeed, the performance reached on a carefully annotated corpus with pharmacokinetics literature is quite high for both abstract classification (reaching $F_1 \approx 0.93, MCC \approx 0.74, iAUC \approx 0.99$) and evidence sentence extraction $(F_1 \approx 0.76, MCC \approx$ 0.65, $iAUC \approx 0.83$). To demonstrate the capability of BLM in the pharmacokinetics DDI context, where there are no previous directly-relevant corpora and experiments, we pursued a thorough comparison of the performance of several linear classifiers using different combinations of unigrams, bigrams, PubMed metadata, and NER features. We also tested the effect of feature transforms methods, as well as dimensionality-reduction.

From a classification performance perspective, some results are noteworthy: in terms of textual features, bigrams in combination with unigrams performed significantly better than unigrams alone. However, performance in unigram versus bigram runs for the same classifier differed by no more than one percent for iAUC and MCC. Thus, while bigram features did contain some additional information about class membership, the amount of this information was not large.

In our experiments, feature transforms and PCA-based dimensionality reductions did not improve overall best performance significantly, but did improve performance significantly for a few of the classifiers, especially "naive" classifiers such as dLDA that assume feature independence. We also found that a sophisticated version of the LDA classifier, which used SVD to eliminate rank-deficiency in the feature occurrence matrices and performed shrinkage of the feature covariance matrix for regularization (see "Materials and Methods"), dominated performance in both the abstract and sentence tasks.

From the drug-interaction domain perspective, feature analysis at the abstract level revealed that pharmacokinetics evidence of DDI in the literature is very correlated with terms that explicitly indicate interaction (including MeSH terms), enzyme inhibitors (including substance names via the RN metadata field in PubMed), DDI administration protocols, and study design. At the sentence level, drug interaction evidence from a pharmacokinetics perspective is very correlated with terms that express experimental results, such as numerical values, measures of drug clearance, expressions of quantitative changes, as well as adverbs expressing significance of evidence. Feature analysis also revealed that lack of DDI evidence in the pharmacokinetics literature (negative class) at the abstract level is highly correlated with some terms from PubMed metadata fields, as well as those pertaining to genomic or general medical terminology. At the sentence level, sentences in relevant abstracts but without DDI evidence tend to include pharmacokinetics protocols as well as more generic interaction discourse or biomedical concepts.

Since many important features came from PubMed metadata fields, to rigorously determine their effect on classification we looked at changes in iAUC scores when features from different PubMed metadata fields were omitted. We showed that only omitting features derived from MeSH significantly affected abstract classification performance. Nonetheless, while statistically significant, the drop in performance is rather small—e.g. affecting only millesimals of the iAUC of abstract classification; therefore, the abstract classification performance relies mostly in the statistics of features obtained from abstract text (e.g. $iAUC \approx 0.98$ without). This is an important consideration, since MeSH terms may not be immediately added to publications – according to ELM statistics, on average it takes 90 days from publication for 75% of articles in PubMed to be indexed with MeSH terms, and some articles are never indexed. Therefore, the systematic classification and evidence extraction from brand new articles may not rely on such metadata.

We also tested the effect of including features extracted with named entity recognition (NER) and dictionary tools potentially relevant to the domain, namely those accounting for chemical, genomic, metabolomic, drug, and pharmacokinetic entities. Generally, dictionaries like BICEPP, i-Drugs, and DrugBank, which counted the number of times drug names appeared, significantly improved performance for several classifiers on abstract classification and evidence sentence extraction. An exception to this was the lack of improvement on abstracts when including DrugBank features, an effect that needs further investigation to understand. Nonetheless, similarly to the use of MESH terms in abstract classification, the performance increases were modest, even if statistically significant. This again demonstrates that relevant-class information can be extracted from abstracts using solely the statistics of textual features (bigrams and unigrams) .

Notably, in both tasks, relevant and irrelevant documents/sentences derive from the pharmacokinetics literature and for this reason share similar feature statistics. This makes distinguishing between them not a trivial text classification problem, though also a more practically relevant one (as in the case of a researcher who needs to automatically label potentially relevant documents retrieved from PubMed). In absolute terms, performance differences between different classifiers, transforms, and dimensionality reductions were not large (even if statistically significant). This indicates a fundamental limit on the amount of statistical signal present in the labels and feature distributions of the corpus as extractable by linear classifiers, especially when classifiers are tuned toward optimal generalization performance using cross-validated regularization parameters. Furthermore, the abstract ranking performance cannot improve much more, given that the $iAUC \approx 0.99$. There is room to improve abstract classification performance, even though both F1 and MCC are quite high for this type of problem. Of course, it is possible that performance could be improved, especially for sentence extraction, through the use of nonlinear classifiers or by using features produced by more finely DDI-tuned NER tools, relation extraction or NLP techniques, or other more sophisticated feature-generation methods.

In general, different classifiers have non-identical generalization performance because they choose separating planes to optimize different cost functions and perform regularization using different penalty terms. However, in our experiments classification performance was robust to the classifier utilized. While the "non-naive" classifiers, which consider feature covariances, significantly outperformed the naive set of classifiers, the performance of the latter class of classifiers was still comparable—the iAUC changes by no more than one percent from best to worst classifier in both the abstract and sentence tasks. This means that a BLM pipeline for this problem would do similarly well independently of classifier chosen. It is worth noticing that an analysis of both abstract- and sentence-trained feature weight coefficients (see Supporting Information) shows systematic differences between weights selected by naive and non-naive classifiers. This also suggests that sentence extraction may improve with larger amounts of training data, permitting better estimates of feature covariances.

A comparison of the performance we obtained with previous experiments in the literature is not easy. First, there is no gold standard for DDI evidence sentence extraction, especially for a specific evidencetype such as pharmacokinetics. Second, most sentence extraction tasks in the biomedical domain involve extraction of passages which can contain several sentences (e.g. the protein-protein interaction subtask in Biocreative II), or passages relevant for a set of specific targets (e.g. Gene Ontology annotations for specific gene names in Biocreative I $[59]$ and IV $[60]$. Due to these difficulties, the performance on those tasks has been comparatively low, e.g. in BioCreative IV the best F1 score in the gene ontology evidence extraction task was 0.27 [\[60\]](#page-22-1) (in Biocreative II, due to possible overlap and multiple accepted passages the preferred performance measure was the mean reciprocal rank which reached 0.87 [\[11,](#page-19-7) [61\]](#page-22-2)). Considering that our performance on the sentence task is higher than what is typically reported for the abstract classification in the biomedical domain (e.g. PPI abstract classification in the BioCreative Challenge III reached $F_1 \approx 0.61$, $MCC \approx 0.55$, $\Delta UC \approx 0.68$ [\[16\]](#page-19-11)), the classifiers trained on our sentence corpus reached a very good level of performance, indicating both that the corpus is well annotated and the task is very feasible. Given the performance of our approach in extracting pharmacokinetic evidence, the classification methodology and associated corpus may actually be useful in the previously-explored task of extracting interacting drug pairs from the literature. Indeed, it may be more effective to first identify sentences with DDI evidence of a specific type, and then extract from them (using the context of a specific type of evidence) the interacting drug names, using automated methods or human expertise.

To conclude, we provide a thorough report of the capability of supervised text classifiers to automatically extract pharmacokinetics evidence of DDI from an abstract- and sentence-level annotated corpus. Given the high performance observed for all classifiers, including the simplest ones, on both abstract and sentence classification, we conclude that automatic BLM techniques can identify reports of DDIs backed by pharmacokinetic evidence in PubMed abstracts, and furthermore extract such evidence from individual sentences under realistic classification scenarios. The sentences with evidence extracted from these reports can be essential in identifying causal mechanics of putative DDIs, and can serve as input for further pharmacological and pharmaco-epidemiology investigation. Our work shows that BLM can be successfully used to extract a particular type of DDI evidence from the published literature, and that this methodology can be safely included in DDI discovery pipelines where attention to distinct types of evidence is necessary. In future work, we intend to demonstrate this methodology on the extraction from text of other types of DDI experimental evidence, with the goal of filling the knowledge gaps that exist in the DDI domain and which currently obstruct the development of alternative safe treatments.

Acknowledgments

The authors thank Shreyas Karnik for help with the preparation of the corpora.

Author Contributions

AK implemented the machine learning framework and analyzed results. AL assisted with extraction of NER terms. LL and HW prepared the text corpora. LL and LMR conceived and designed the experiments. AK and LMR wrote the paper.

References

- 1. Hall J, DeFrances C, Williams S, Golosinskiy A, Schwartzman A (2010) National hospital discharge survey: 2007 summary. National Health Statistics Reports : 1-20.
- 2. Nisha R, Bhuiya F, Xu J (2010) National hospital ambulatory medical care survey: 2007 emergency department summary. National Health Statistics Reports : 1-32.
- 3. Becker M, et al. (2007) Hospitalisations and emergency department visits due to drug–drug interactions: a literature review. Pharmacoepidemiol Drug Saf 16: 641–651.
- 4. Percha B, Altman R (2013) Informatics confronts drug-drug interactions. Trends in Pharmacological Sciences 34: 178-184.
- 5. Jankel C, Fitterman L (1993) Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug safety 9: 51.
- 6. Leape L, et al. (1995) Systems analysis of adverse drug events. JAMA 274: 35–43.
- 7. Hajjar E, Cafiero A, Hanlon J (2007) Polypharmacy in elderly patients. Am J Geriatr Pharmacother 5: 345–351.
- 8. Boyce R, Collins C, Horn J, Kalet I (2009) Computing with evidence part i: A drug-mechanism evidence taxonomy oriented toward confidence assignment. J Biomed Inform 42: 979-989.
- 9. Boyce R, Collins C, Horn J, Kale I (2009) Computing with evidence part ii: An evidential approach to predicting metabolic drug-drug interactioncomputing with evidence part ii: An evidential approach to predicting metabolic drug-drug interactions. J Biomed Inform 42: 990-1003.
- 10. Hennessy S, Flockhart D (2012) The need for translational research on drug-drug interactions. Clinical Pharmacology and Therapeutics 91: 771-773.
- 11. Abi-Haidar A, et al. (2008) Uncovering protein interaction in abstracts and text using a novel linear model and word proximity networks. Genome Biology 9: S11.
- 12. Shatkay H, Feldman R (2003) Mining the biomedical literature in the genomic era: an overview. Journal of Computational Biology 10: 821–855.
- 13. Jensen L, et al. (2006) Literature mining for the biologist: from information retrieval to biological discovery. Nature Reviews Genetics 7: 119–129.
- 14. Cohen K, Hunter L (2008) Getting started in text mining. PLoS Comput Biol 4: e20.
- 15. Leitner F, et al. (2010) The febs letters/biocreative ii. 5 experiment: making biological information accessible. Nature Biotechnology 28: 897–899.
- 16. Krallinger M, et al. (2011) The protein-protein interaction tasks of biocreative iii: classification/ranking of articles and linking bio-ontology concepts to full text. BMC bioinformatics 12: S3.
- 17. Rechtsteiner A, et al. (2006) Use of text mining for protein structure prediction and functional annotation in lack of sequence homology. In: Joint BioLINK and Bio-Ontologies Meeting (ISMB Special Interest Group).
- 18. McDonald R, et al. (2004) An entity tagger for recognizing acquired genomic variations in cancer literature. Bioinformatics 20: 3249–3251.
- 19. El-Shishiny H, et al. (2008) Mining drug targets based on microarray experiments. In: Computers and Communications, IEEE Symposium on. IEEE, pp. 175–181.
- 20. Tatonetti N, et al. (2011) Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels. Clinical Pharmacology & Therapeutics 90: 133–142.
- 21. Segura-Bedmar I, et al. (2010) Resolving anaphoras for the extraction of drug-drug interactions in pharmacological documents. BMC Bioinformatics 11: S1.
- 22. Percha B, Garten Y, Altman R (2012) Discovery and explanation of drug-drug interactions via text mining. In: Pacific Symposium on Biocomputing. p. 410.
- 23. Duke J, Han X, Wang Z, Subhadarshini A, Karnik S, et al. (2012) Drug interaction prediction from literatures and clinical significance assessment in medical records. PLoS Comput Biol 8: e1002614.
- 24. Segura-Bedmar I, Martínez P, de Pablo-Sánchez C (2011) A linguistic rule-based approach to extract drug-drug interactions from pharmacological documents. BMC Bioinformatics 12: S1.
- 25. Segura-Bedmar I, Martínez P, de Pablo-Sánchez C (2011) Using a shallow linguistic kernel for drug-drug interaction extraction. J Biomed Inform 44: 789-804.
- 26. Wu H, Karnik S, Subhadarshini A, Wang Z, Philips S, et al. (2013) An integrated pharmacokinetics ontology and corpus for text mining. BMC Bioinformatics 14: 35.
- 27. Segura-Bedmar I, Martínez P, Herrero-Zazo M (2014) Lessons learnt from the ddiextraction-2013 shared task. Journal of biomedical informatics .
- 28. Herrero-Zazo M, Segura-Bedmar I, Martínez P, Declerck T (2013) The ddi corpus: An annotated corpus with pharmacological substances and drug–drug interactions. Journal of biomedical informatics 46: 914–920.
- 29. Tatonetti N, et al. (2012) Data-driven prediction of drug effects and interactions. Sci Transl Med 4: 125ra31–125ra31.
- 30. Wang Z, et al. (2009) Literature mining on pharmacokinetics numerical data: A feasibility study. J Biomed Inform 42: 726–735.
- 31. Kolchinsky A, et al. (2013) Evaluation of linear classifiers on articles containing pharmacokinetic evidence of drug-drug interactions. Pacific Symposium on Biocomputing 18: 409-420.
- 32. Wall ME, Rechtsteiner A, Rocha LM (2003) Singular value decomposition and principal component analysis. In: DP Berrar MG W Dubitzky, editor, A Practical Approach to Microarray Data Analysis, KluwerKluwer: Norwell, MA. pp. 91-109.
- 33. Ddi-extraction-2011. URL <http://labda.inf.uc3m.es/DDIExtraction2011>.
- 34. Ddi-extraction-2013. URL <http://www.cs.york.ac.uk/semeval2013/task9>.
- 35. Segura-Bedmar I, Martınez P, Sánchez-Cisneros D (2011) The 1st ddiextraction-2011 challenge task: Extraction of drug-drug interactions from biomedical texts. Challenge Task on Drug-Drug Interaction Extraction 2011: 1–9.
- 36. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, et al. (2008) Drugbank: a knowledgebase for drugs, drug actions and drug targets. Nucleic acids research 36: D901–D906.
- 37. Tari L, Anwar S, Liang S, Cai J, Baral C (2010) Discovering drug-drug interactions: a text-mining and reasoning approach based on properties of drug metabolism. Bioinformatics 26: i547-553.
- 38. Cheng F, Zhao Z (2014) Machine learning-based prediction of drugŰdrug interactions by integrating drug phenotypic, therapeutic, chemical, and genomic properties. Journal of the American Medical Informatics Association 21: e278-e286.
- 39. Gonzalez G, Cohen K, Greene C, Kann M, Leaman R, et al. (2013) Text and data mining for biomedical discovery-session introduction. In: Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing. volume 19, pp. 312–315.
- 40. Gonzalez G, Cohen KB, Greene CS, Hahn U, Kann MG, et al. (2012) Text and data mining for biomedical discovery. In: Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing. World Scientific, pp. 368–372.
- 41. Lourenço A, et al. (2011) A linear classifier based on entity recognition tools and a statistical approach to method extraction in the protein-protein interaction literature. BMC Bioinformatics 12: S12.
- 42. Kolchinsky A, et al. (2010) Classification of protein-protein interaction full-text documents using text and citation network features. IEEE/ACM Trans Comput Biol Bioinf 7: 400–411.
- 43. Pharmacokinetic corpus. URL <http://rweb.compbio.iupui.edu/corpus/downloads.html>.
- 44. Porter M, et al. (1980). An algorithm for suffix stripping.
- 45. Bishop CM (2006) Pattern Recognition and Machine Learning. Springer.
- 46. Pedregosa F, et al. (2011) Scikit-learn: Machine Learning in Python . JMLR 12: 2825–2830.
- 47. Fan R, et al. (2008) Liblinear: A library for large linear classification. JMLR 9: 1871–1874.
- 48. Ye J, et al. (2006) Efficient model selection for regularized linear discriminant analysis. In: Proc the 15th ACM international conference on Information and knowledge management. ACM, pp. 532–539.
- 49. Bickel P, Levina E (2004) Some theory for fisher's linear discriminant function, 'naive bayes', and some alternatives when there are many more variables than observations. Bernoulli 10: 989–1010.
- 50. Leopold E, Kindermann J (2002) Text categorization with support vector machines. how to represent texts in input space? Machine Learning 46: 423–444.
- 51. Matthews B, et al. (1975) Comparison of the predicted and observed secondary structure of t4 phage lysozyme. Biochimica et biophysica acta 405: 442.
- 52. Baldi P (2000) Assessing the accuracy of prediction algorithms for classification: an overview. Bioinformatics 16: 412–424.
- 53. Davis J, Goadrich M (2006) The relationship between precision-recall and roc curves. In: ICML 23. ACM, pp. 233–240.
- 54. Agresti A (2007) An introduction to categorical data analysis. Wiley-Interscience.
- 55. Jessop D, Adams S, Willighagen E, Hawizy L, Murray-Rust P (2011) Oscar4: a flexible architecture for chemical text-mining. J Cheminf 3: 1–12.
- 56. Settles B (2005) Abner: an open source tool for automatically tagging genes, proteins and other entity names in text. Bioinformatics 21: 3191–3192.
- 57. Lin F, et al. (2011) Bicepp: an example-based statistical text mining method for predicting the binary characteristics of drugs. BMC Bioinformatics 12: 112.
- 58. Wishart D, et al. (2006) Drugbank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Research 34: D668–D672.
- 59. Hirschman L, Yeh A, Blaschke C, Valencia A (2005) Overview of biocreative: critical assessment of information extraction for biology. BMC bioinformatics 6: S1.
- 60. Mao Y, Van Auken K, Li D, Arighi CN, Lu Z (2013) The gene ontology task at biocreative iv. In: Proceedings of the Fourth Biocreative Challenge Evaluation Workshop. volume 1, pp. 119–127.
- 61. Krallinger M, Leitner F, Rodriguez-Penagos C, Valencia A, et al. (2008) Overview of the proteinprotein interaction annotation extraction task of biocreative ii. Genome biology 9: S4.
- 62. Zhu J, Hastie T (2001) Kernel logistic regression and the import vector machine. Advances in neural information processing systems 14: 1081–1088.

Extraction of Pharmacokinetic Evidence of Drug-drug Interactions from the Literature: SUPPORTING INFORMATION

Artemy Kolchinsky, Anália Lourenço, Heng-Yi Wu, Lang Li, Luis M. Rocha

1 Abstract performance

The following table lists classification performance according to F1, MCC, iAUC, and Accuracy measures of the different classifiers on unigram and bigram abstract runs. It includes the VTTcv classifier (VTT with a cross-validated threshold), which is not discussed in depth in the main article.

1.1 Abstract performance: Feature transforms and dimensionality reduction

The following charts show the iAUC, F1, and MCC performance performance on the bigram runs when feature transforms and dimensionality reductions are applied. Stars mark those configurations that performed significantly better $(p<0.05,$ one-tailed test) than the no-transform, no-dimensionality-reduction configuration of the same classifier (marked with larger circles). Naive Bayes was not tested since it is only applicable to binary data, and VTT was only tested on the sparse transforms (i.e., with no PCA-based dimensionality reduction).

1.2 Abstract Performance: Most relevant and irrelevant features

A linear classifier separates classes using a hyperplane defined by a set of feature coefficients. The impact of a given feature on classification is naturally quantified by the sign and amplitude of its hyperplane coefficient. The increase of the value of a feature with a large positive (negative) coefficient produces a large increase in a document's propensity to be classified as relevant (irrelevant). However, in our conditions, these coefficients apply to data sets with very different statistics. They are made more comparable by an appropriate normalization: we multiply each feature's coefficient by the standard deviation of the feature's values in the training data, producing what is referred to as a 'standardized coefficient' in the linear regression literature. For the abstract bigram runs, the following figure shows the ranks of the most relevant and the reverse rank of the most irrelevant features. RELEVANT FEATURES includes any feature whose standardized coefficient was among the top 5 most positive standardized coefficients for any transform/classifier combination, while IRRELEVANT FEATURES includes any whose standardized coefficient was among the top 5 most negative. Transforms are organized in the vertical columns, while classifiers are distinguished by color and marker style. Markers are positioned according to their rank among the most positive or negative features for a given classifier and transform combination.

A linear classifier separates document classes using a hyperplane defined by a set of feature coefficients, with the impact of a given feature on classification being quantified by the sign and amplitude of its hyperplane coefficient. To further compare the importance that different classifier/transform combinations gave to different features, we performed principal component analysis on a matrix composed of the hyperplane coefficients for all such combinations. The following figure plots each transform-classifier hyperplane in terms of its loading on the first two principal components (PCs). The PC projection separates classifiers that use feature covariance information (LDA, SVM, and Logistic Regression) and those that don't (Naive Bayes, dLDA, VTT) . It also tends to organize configurations according to feature transforms, with configurations that included IDF-like transforms clustering separately from those with no-transforms or simple L2-normalization. In general, SVM and Logistic Regression produce very similar feature loadings, which is not surprising given that they optimize closely-related cost functions during training [\[62\]](#page-22-3).

1.3 Abstract Performance: NER and Metadata Features

The following figures plot the relative changes in performance when including vs. not-including metadata and NER-derived features on non-transformed abstract bigram runs, according to F1 and MCC measures. Significant changes (p<0.05, two-tailed test) indicated by asterisks. For metadata, changes in performance are measured while still including features from the other 4 metadata fields.

2 Sentence performance

The following table lists classification performance according to F1, MCC, iAUC, and Accuracy measures of the different classifiers on unigram and bigram sentence runs. It includes the VTTcv classifier (VTT with a cross-validated threshold), which is not discussed in depth in the main article.

2.1 Sentence performance: Feature transforms and dimensionality reduction

The following charts show the F1 and MCC performance performance on the bigram runs when feature transforms and dimensionality reductions are applied. Significant improvements ($p < 0.05$, one-tailed test) compared to the same classifier applied to non-transformed data indicated by stars.

2.2 Sentence Performance: Most relevant and irrelevant features

We analyzed which features were most relevant and irrelevant for identifying evidence sentences, using the same methodology as for abstracts, as described in section 2.2. In the following figure, RELEVANT FEATURES includes any feature whose standardized coefficient was among the top 5 most positive standardized coefficients for any transform/classifier combination, while IRRELEVANT FEATURES includes any whose standardized coefficient was among the top 5 most negative. Transforms are organized in the vertical columns, while classifiers are distinguished by color and marker style. Markers are positioned according to their rank among the most positive or negative features for a given classifier and transform combination.

As in section 1.2, we perform principal component analysis of transforms and classifiers trained on the sentence corpus. Similarly to abstracts, we find the classifiers that do not use feature covariances (VTT, dLDA, Naive Bayes) cluster separately from those that do (LDA, SVM, Logistic Regression). The second principal components separates hyperplanes according to the classifier by which they were generated.

2.3 Sentence Performance: Impact of NER Features

The following figures plot the relative changes in performance when including vs. not-including NERderived features on non-transformed sentence bigram runs, according to F1 and MCC measures. Significant changes ($p < 0.05$, two-tailed test) indicated by asterisks.

